Galectin Therapeutics (GALT) Current Assets (2010 - 2026)

Galectin Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• In Q1 2026, Current Assets rose 68.99% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $15.7 million (up 68.99% YoY), while the FY2025 annual figure was $19.4 million, up 12.66% from the prior year.
• Current Assets was $15.7 million for Q1 2026 at Galectin Therapeutics, down from $19.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $33.5 million in Q1 2022 to a low of $9.3 million in Q1 2025.
• Historically, Current Assets has averaged $21.0 million across 5 years, with a median of $19.6 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Current Assets slumped 63.53% in 2025, then surged 68.99% in 2026.
• A 5-year view of Current Assets shows it stood at $20.6 million in 2022, then soared by 34.83% to $27.7 million in 2023, then slumped by 37.74% to $17.3 million in 2024, then rose by 12.66% to $19.4 million in 2025, then fell by 19.27% to $15.7 million in 2026.
• The last three Current Assets figures came in at $15.7 million (Q1 2026), $19.4 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.